Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HepatoPredict

Financiado

Cerrado

HepatoPredict A decision tool for Liver Transplantation based on molecular sign...

HepatoPredict A decision tool for Liver Transplantation based on molecular signature Hepatocellular carcinoma (HCC) is a leading cause of cancer related mortality world-wide. The best curative treatment option is liver transplantation. The need for liver transplants for HCC by far exceeds the number of available o... ver más

30/04/2022

OPHIOMICS

1M€

Presupuesto del proyecto: 1M€

Líder del proyecto

OPHIOMICS INVESTIGACAO E DESENVOLVIMENTO EM... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 3 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2022-04-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

3 Participantes

OPHIOMICS

756.96K€ | Lider

EXPOSICIÓN Y CONSERVACIÓN DE...

202.20K€ | Participante

TECNOLOGIA ELECTROSTATICA E...

Proyectos interesantes

HepatoPredict

Medical Technol...

Data Science

71K€ Cerrado

LEOPARD

Medical Technol...

Artificial Inte...

7M€ Cerrado

PID2021-125573OB-I00

Medical Technol...

Data Science

91K€ Cerrado

AI CARE

Medical Technol...

Data Science

2M€ Cerrado

HEPCIR

Medical Technol...

Data Science

2M€ Cerrado

EU-TRAIN

Medical Technol...

Data Science

7M€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 24 meses Fecha Inicio: 2020-04-20
Fecha Fin: 2022-04-30

Líder del proyecto

OPHIOMICS INVESTIGACAO E DESENVOLVIMENTO EM... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 1M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Hepatocellular carcinoma (HCC) is a leading cause of cancer related mortality world-wide. The best curative treatment option is liver transplantation. The need for liver transplants for HCC by far exceeds the number of available organs, so stringent selection criteria are of paramount importance in order to ensure that the best candidates are selected for the procedure. So far, clinicians have to rely only on clinical variables to select transplant candidates for liver transplantation. The current criteria used (MILAN and San Francisco criteria) limits transplant to patients within specific parameters as tumour number and diameter, clearly related to disease and tumour biological behavior, but can only act as surrogate markers of tumour stage and biology. Hence, it is not possible to predict which patients outside the Milan or San Francisco criteria that would have a favourable prognosis. On this background, it is of outmost importance to gain access to better predictive tools that can provide decision support in selection for these patients. In response to this challenge, Ophiomics has developed a powerful predictive tool (HepatoPredict) based on molecular signature and clinical parameters, rather than only clinical variables. We can predict the good outcome of the intervention with a successful-curative rate of 95%, improving the Milan and San Francisco criteria (67%). Unsuccessful liver transplantation will be avoided and, as a consequence, better survival rate and more saved lives will be achieved. Upon 5 years after the completion of the project, HepatoPredict will boost the growth of our company generating additional 27 employees and a ROI of 13.82. With the help of SME instrument, Ophiomics aims to complete the clinical validation and product optimization so that it can be commercialized across European markets first, and global markets later on, improving the quality of care of healthcare systems worldwide as well as the HCC patient ́s quality of life.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores